A-62176, a potent topoisomerase inhibitor, inhibits the expression of human epidermal growth factor receptor 2

Cancer Letters

Volumn 325, Issue 1, 2012, Pages 72-79

  Kim, Hye Lin ^a   Jeon, Kyung Hwa ^a   Jun, Kyu Yeon ^a   Choi, Yongmun ^b   Kim, Dae Kee ^a   Na, Younghwa ^c   Kwon, Youngjoo ^a  

^a Ewha Womans University   (South Korea)

^b Gyeonggi Institute of Science and Technology Promotion   (South Korea)

^c Cha University   (South Korea)

Author keywords

Fluoroquinophenoxazine derivative; Gastric cancer; Human epidermal growth factor receptor 2; Topoisomerase II

Indexed keywords

1 (3 AMINO 1 PYRROLIDINYL) 2 FLUORO 4 OXO 4H QUINO[8,1A,1 B,C][1,4]BENZOXAZINE 5 CARBOXYLIC ACID; 4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; CANERTINIB; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; PACLITAXEL; PROTEIN KINASE B; TRANSCRIPTION FACTOR ESX; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR SUR2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; DOWN REGULATION; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; STOMACH CANCER; UPREGULATION;

ANTIGENS, NEOPLASM; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLIN D1; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOWN-REGULATION; DOXORUBICIN; G1 PHASE; HEK293 CELLS; HUMANS; MEDIATOR COMPLEX; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; OXAZINES; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLONES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TOPOISOMERASE INHIBITORS; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84865304154     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.06.004     Document Type: Article

References (41)

1. Scholl S., Beuzeboc P., Pouillart P. Targeting HER2 in other tumor types. Ann. Oncol. 2001, 12:S81-S87.
2. Tai W., Mahato R., Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J. Control Release 2010, 146:264-275.
3. Carpenter G., Cohen S. Epidermal growth. J. Biol. Chem. 1990, 265:7709-7712.
4. Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin. Breast Cancer 2008, 8:324-333.
5. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20:719-726.
6. Hynes N.E., MacDonald G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 2009, 21:177-184. (references therein).
7. Nahta R., Yu D., Hung M.C., Hortobagyi G.N., Esteva F.J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol. 2006, 3:269-280. (references therein).
8. Spector N.L., Blackwell K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 2009, 27:5838-5847. (references therein).
9. Fang L., Barekati Z., Zhang B., Liu Z., Zhong X.Y. Targeted therapy in breast cancer: what's new?. Swiss Med. Wkly. 2011, 141:w13231.
10. Chen F.L., Xia W., Spector N.L. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin. Cancer Res. 2008, 14:6730-6734.
11. Allgayer H., Babic R., Gruetzner K.U., Tarabichi A., Schildberg F.W., Heiss M.M. C-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J. Clin. Oncol. 2000, 18:2201-2209.
12. Chua T.C., Merrett N.D. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes - a systematic review. Int. J. Cancer 2011, 10.1002/ijc.26292.
13. Morphy R., Rankovic Z. Fragments, network biology and designing multiple ligands. Drug Discov. Today 2007, 12:156-160.
14. Paik S., Bryant J., Park C., Fisher B., Tan-Chiu E., Hyams D., Fisher E.R., Lippman M.E., Wickerham D.L., Wolmark N. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl. Cancer Inst. 1998, 90:1361-1370.
15. Mano M.S., Rosa D.D., De Azambuja E., Ismael G.F., Durbecq V. The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. Cancer Treat. Rev. 2006, 33:64-77.
16. Corbett K.D., Berger J.M. Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu. Rev. Biophys. Biomol. Struct. 2004, 33:95-118.
17. Furet P., Schoepfer J., Radimerski T., Chène P. Discovery of a new class of catalytic topoisomerase II inhibitors targeting the ATP-binding site by structure based design. Part I. Bioorg. Med. Chem. Lett. 2009, 19:4014-4017.
18. Jun K.Y., Lee E., Jung M.J., Lee O.H., Lee E.S., Park Choo H.Y., Na Y., Kwon Y. Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor. Eur. J. Med. Chem. 2011, 46:1964-1971.
19. Kanta S.Y., Yamane T., Dobashi Y., Mitsui F., Kono K., Ooi A. Topoisomerase II alpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum. Pathol. 2006, 37:1333-1343.
20. Järvinen T.A., Tanner M., Rantanen V., Bärlund M., Borg A., Grénman S., Isola J. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 2000, 156:839-847.
21. Shimogawa H., Kwon Y., Mao Q., Kawazoe Y., Choi Y., Asada S., Kigoshi H., Uesugi M. A wrench-shaped synthetic molecule that modulates a transcription factor-coactivator interaction. J. Am. Chem. Soc. 2004, 126:3461-3471.
22. Cho H.J., Jung M.J., Kwon Y., Na Y. Oxiranylmethyloxy or thiiranylmethyloxy-azaxanthones and -acridone analogues as potential topoisomerase I inhibitors. Bioorg. Med. Chem. Lett. 2009, 19:6766-6769.
23. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
24. Asada S., Choi Y., Yamada M., Wang S.C., Hung M.C., Qin J., Uesugi M. External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. Proc. Natl. Acad. Sci. USA 2002, 99:12747-12752.
25. Kang D.H., Kim J.S., Jung M.J., Lee E.S., Jahng Y., Kwon Y., Na Y. New insight for fluoroquinophenoxazine derivatives as possibly new potent topoisomerase I inhibitor. Bioorg. Med. Chem. Lett. 2008, 18:1520-1524.
26. Spector N., Xia W., El-Hariry I., Yarden Y., Bacus S. HER2 therapy Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res. 2007, 9:205.
27. Kim J.W., Kim H.P., Im S.A., Kang S., Hur H.S., Yoon Y.K., Oh D.Y., Kim J.H., Lee D.S., Kim T.Y., Bang Y.J. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett. 2008, 272:296-306.
28. Hughes D.P., Thomas D.G., Giordano T.J., McDonagh K.T., Baker L.H. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr. Blood Cancer 2006, 46:614-623.
29. Kwon Y.K., Bhattacharyya A., Alberta J.A., Giannobile W.V., Cheon K., Stiles C.D., Pomeroy S.L. Activation of ErbB2 during wallerian degeneration of sciatic nerve. J. Neurosci. 1997, 17:8293-8299.
30. Meloche S., Pouysségur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007, 26:3227-3239.
31. Gesbert F., Sellers W.R., Signoretti S., Loda M., Griffin J.D. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-kinase/AKT pathway. J. Biol. Chem. 2000, 275:39223-39230.
32. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., Sliwkowski M.X., Stern H.M. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008, 68:5878-5887.
33. Trinks C., Djerf E.A., Hallbeck A.L., Jönsson J.I., Walz T.M. The pan-ErbB receptor tyrosine kinase inhibitor canertinib induces ErbB-independent apoptosis in human leukemia (HL-60 and U-937) cells. Biochem. Biophys. Res. Commun. 2010, 393:6-10.
34. Drake F.H., Hofmann G.A., Bartus H.F., Mattern M.R., Crooke S.T., Mirabelli C.K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989, 28:8154-8160.
35. SandriI M.I., Hochhauser D., Ayton P., Camplejohn R.C., Whitehouse R., Turley H., Gatter K., Hickson I.D., Harris A.L. Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. Brit. J. Cancer 1996, 73:1518-1524.
36. Shpitz B., Bomstein Y., Zehavi T., Bernheim J., Liverant S., Kaufman Z., Buklan G., Klein E. Topoisomerase IIα expression in ductal carcinoma in situ of the breast: a preliminary study. Hum. Pathol. 2000, 31:1249-1254.
37. Bhargava R., Naeem R., Marconi S., Luszcz J., Garb J., Gasparini R., Otis C.N. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression. Hum. Pathol. 2001, 32:1344-1350.
38. Fumoleau P., Coudert B., Isambert N., Ferrant E. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann. Oncol. 2007, 18:v9-15.
39. Frezza M., Hindo S., Chen D., Davenport A., Schmitt S., Tomco D., Dou Q.P. Novel metals and metal complexes as platforms for cancer therapy. Curr. Pharm. Des. 2010, 16:1813-1825.
40. Pegram M., Hsu S., Lewis G., Pietras R., Beryt M., Sliwkowski M., Coombs D., Baly D., Kabbinavar F., Slamon D. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999, 18:2241-2251.
41. Gieseg M.A., de Bock C., Ferguson L.R., Denny W.A. Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. Anticancer Drugs 2001, 2:683-690.